High-dose melphalan for multiple myeloma: long-term follow-up data.

Abstract

Single-agent HDM without autologous bone marrow transplantation is a feasible therapeutic option in myeloma, and is associated with a high objective response rate, relatively long remission durations, and good symptom control.